Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Immupharma confirms £8.4mln fundraise

Shares in ImmuPharma nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.
Immupharma confirms £8.4mln fundraise
Immupharma brought in £8.4mln from the placing and subscription

Shares in ImmuPharma (LON:IMM) nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.

It comes after it did receive VCT advance assurance and EIS advance assurances from HMRC which it required to raise a further £0.7mln.

The cash will be used to fund its share of the costs of developing Lupuzor, its potential blockbuster drug for the autoimmune disease Lupus, which is currently undergoing phase III clinical trials and also provide the firm with its working capital requirements through to 2018.

Shares added 2.06% on Tuesday Morning to stand at 24.75p.

Giles_55af4ddca6481.jpg
Why Invest In ImmuPharma PLC? Read More Here

Register here to be notified of future IMM Company articles
View full IMM profile

ImmuPharma PLC Timeline

Related Articles

1-SG02055.jpg
March 22 2016
e-Therapeutics is now targeting partners to accelerate the development of its drug discovery engine and commercialise compounds.
immupharma-_kiss_pic_with_mum.png
March 01 2016
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
Knee surgery
July 13 2016
The treatment involves removing cellular material from animal and human tissue to leave a matrix which gives a framework for population by the patient’s own cells.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.